An Update on the Pharmacogenomics of Metformin: Progress, Problems and Potential

• Danaei G , FinucaneMM, LuY et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785) , 31–40 (2011).
   PubMed Web of Science ®Google Scholar
• Inzucchi SE , BergenstalRM, BuseJB et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6) , 1364–1379 (2012).
   PubMed Web of Science ®Google Scholar
• Graham GG , PuntJ, AroraM et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50(2) , 81–98 (2011).
   PubMed Web of Science ®Google Scholar
• Viollet B , GuigasB, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.)122(6) , 253–270 (2012).
   PubMed Web of Science ®Google Scholar
• Gong L , GoswamiS, GiacominiKM, AltmanRB, KleinTE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics22(11) , 820–827 (2012).
   PubMed Web of Science ®Google Scholar
• Rena G , PearsonER, SakamotoK. Molecular mechanism of action of metformin: old or new insights? Diabetologia56(9) , 1898–1906 (2013).
   PubMed Web of Science ®Google Scholar
• Bailey CJ . Biguanides and NIDDM. Diabetes Care15(6) , 755–772 (1992).
   PubMed Web of Science ®Google Scholar
• Stumvoll M , NurjhanN, PerrielloG, DaileyG, GerichJE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med.333(9) , 550–554 (1995).
   PubMed Web of Science ®Google Scholar
• Bailey CJ , TurnerRC. Metformin. N. Engl. J. Med.334(9) , 574–579 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou G , MyersR, LiY et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8) , 1167–1174 (2001).
   PubMed Web of Science ®Google Scholar
• Shaw RJ , LamiaKA, VasquezD et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754) , 1642–1646 (2005).
   PubMed Web of Science ®Google Scholar
• Foretz M , HebrardS, LeclercJ et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120(7) , 2355–2369 (2010).
   PubMed Web of Science ®Google Scholar
• Owen MR , DoranE, HalestrapAP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J.348(Pt 3) , 607–614 (2000).
   PubMed Web of Science ®Google Scholar
• El-Mir MY , NogueiraV, FontaineE, AveretN, RigouletM, LeverveX. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem.275(1) , 223–228 (2000).
   PubMed Web of Science ®Google Scholar
• Stephenne X , ForetzM, TaleuxN et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54(12) , 3101–3110 (2011).
   PubMed Web of Science ®Google Scholar
• Hawley SA , RossFA, ChevtzoffC et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11(6) , 554–565 (2010).
   PubMed Web of Science ®Google Scholar
• Miller RA , ChuQ, XieJ, ForetzM, ViolletB, BirnbaumMJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature494(7436) , 256–260 (2013).
   PubMed Web of Science ®Google Scholar
• Zhou M , XiaL, WangJ. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab. Dispos. Biol. Fate Chem.35(10) , 1956–1962 (2007).
   PubMed Web of Science ®Google Scholar
• Muller J , LipsKS, MetznerL, NeubertRH, KoepsellH, BrandschM. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol.70(12) , 1851–1860 (2005).
   PubMed Web of Science ®Google Scholar
• Chen L , PawlikowskiB, SchlessingerA et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet. Genomics 20(11) , 687–699 (2010).
   PubMed Web of Science ®Google Scholar
• Nies AT , KoepsellH, WinterS et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50(4) , 1227–1240 (2009).
   PubMed Web of Science ®Google Scholar
• Shu Y , SheardownSA, BrownC et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117(5) , 1422–1431 (2007).
   PubMed Web of Science ®Google Scholar
• Otsuka M , MatsumotoT, MorimotoR, AriokaS, OmoteH, MoriyamaY. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl Acad. Sci. USA102(50) , 17923–17928 (2005).
   PubMed Web of Science ®Google Scholar
• Tanihara Y , MasudaS, SatoT, KatsuraT, OgawaO, InuiK. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol.74(2) , 359–371 (2007).
   PubMed Web of Science ®Google Scholar
• Takane H , ShikataE, OtsuboK, HiguchiS, IeiriI. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics9(4) , 415–422 (2008).
   PubMed Web of Science ®Google Scholar
• Masuda S , TeradaT, YonezawaA et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17(8) , 2127–2135 (2006).
   PubMed Web of Science ®Google Scholar
• Kerb R , BrinkmannU, ChatskaiaN et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12(8) , 591–595 (2002).
   PubMedGoogle Scholar
• Leabman MK , HuangCC, KawamotoM et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12(5) , 395–405 (2002).
   PubMedGoogle Scholar
• Sakata T , AnzaiN, ShinHJ et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun. 313(3) , 789–793 (2004).
   PubMed Web of Science ®Google Scholar
• Shu Y , LeabmanMK, FengB et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl Acad. Sci. USA 100(10) , 5902–5907 (2003).
   PubMed Web of Science ®Google Scholar
• Shu Y , BrownC, CastroRA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2) , 273–280 (2008).
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV , VormfeldeSV, BalenD et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86(3) , 299–306 (2009).
   PubMed Web of Science ®Google Scholar
• Shikata E , YamamotoR, TakaneH et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 52(2) , 117–122 (2007).
   PubMed Web of Science ®Google Scholar
• Becker ML , VisserLE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J.9(4) , 242–247 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou K , DonnellyLA, KimberCH et al. Reduced function SLC22A1 polymorphisms encoding organic cation transporter 1 (OCT1) and glycaemic response to metformin: a Go-DARTS study. Diabetes 58(6) , 1434–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Christensen MM , Brasch-AndersenC, GreenH et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet. Genomics 21(12) , 837–850 (2011).
   PubMed Web of Science ®Google Scholar
• Gram J , HenriksenJE, GrodumE et al. Pharmacological treatment of the pathogenetic defects in Type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 34(1) , 27–33 (2011).
   PubMed Web of Science ®Google Scholar
• Tkáč I , KlimcakovaL, JavorskyM et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in Type 2 diabetes. Diabetes Obes. Metab. 15(2) , 189–191 (2013).
   PubMed Web of Science ®Google Scholar
• Gambineri A , TomassoniF, GaspariniDI et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95(10) , E204–E208 (2010).
   PubMed Web of Science ®Google Scholar
• Jablonski KA , McateerJB, De Bakker PI et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle interventions in the diabetes prevention program. Diabetes59(10) , 2672–2681 (2010).
   PubMed Web of Science ®Google Scholar
• Tarasova L , KalninaI, GeldnereK et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated Type 2 diabetes patients. Pharmacogenet. Genomics 22(9) , 659–666 (2012).
   PubMed Web of Science ®Google Scholar
• Kang HJ , SongIS, ShinHJ et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos. Biol. Fate Chem. 35(4) , 667–675 (2007).
   PubMed Web of Science ®Google Scholar
• Song IS , ShinHJ, ShimEJ et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84(5) , 559–562 (2008).
   PubMed Web of Science ®Google Scholar
• Wang ZJ , YinOQ, TomlinsonB, ChowMS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics18(7) , 637–645 (2008).
   PubMed Web of Science ®Google Scholar
• Chen Y , LiS, BrownC et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 19(7) , 497–504 (2009).
   PubMed Web of Science ®Google Scholar
• Christensen MM , PedersenRS, StageTB et al. A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet. Genomics 23(10) , 526–534 (2013).
   PubMed Web of Science ®Google Scholar
• Kajiwara M , TeradaT, OgasawaraK et al. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J. Hum. Genet. 54(1) , 40–46 (2009).
   PubMed Web of Science ®Google Scholar
• Toyama K , YonezawaA, TsudaM et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet. Genomics 20(2) , 135–138 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y , TeranishiK, LiS et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 9(2) , 127–136 (2009).
   PubMed Web of Science ®Google Scholar
• Choi JH , YeeSW, RamirezAH et al. A common 5´-UTR variant in MATE2-K is associated with poor response to metformin. Clin. Pharmacol. Ther. 90(5) , 674–684 (2011).
   PubMed Web of Science ®Google Scholar
• Ha Choi J , Wah Yee S, Kim MJ et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet. Genomics19(10) , 770–780 (2009).
   PubMed Web of Science ®Google Scholar
• Stocker SL , MorrisseyKM, YeeSW et al. The effect of novelpromoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin. Pharmacol. Ther. 93(2) , 186–194 (2013).
   PubMed Web of Science ®Google Scholar
• Becker ML , VisserLE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes58(3) , 745–749 (2009).
   PubMed Web of Science ®Google Scholar
• Legro RS , BarnhartHX, SchlaffWD et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 93(3) , 792–800 (2008).
   PubMed Web of Science ®Google Scholar
• Dong M , GongZC, DaiXP et al. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus Type 2. Clin. Exp. Pharmacol. Physiol. 38(12) , 824–829 (2011).
   PubMed Web of Science ®Google Scholar
• Zhou K , BellenguezC, SpencerCC et al. Common variants near ATM are associated with glycemic response to metformin in Type 2 diabetes. Nat. Genet. 43(2) , 117–120 (2011).
   PubMed Web of Science ®Google Scholar
• Yee SW , ChenL, GiacominiKM. The role of ATM in response to metformin treatment and activation of AMPK. Nat. Genet.44(4) , 359–360 (2012).
   PubMed Web of Science ®Google Scholar

▪ Website

• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, GA, USA (2011). www.cdc.gov/diabetes/pubs/factsheet11.htm
   Google Scholar